Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: An evidence review group perspective of a NICE single technology appraisal
Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: An evidence review group perspective of a NICE single technology appraisal
As part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) process, the manufacturer of reslizumab (Teva) submitted evidence for its clinical and cost effectiveness for the treatment of eosinophilic asthma inadequately controlled by inhaled corticosteroids. NICE commissioned Southampton Health Technology Assessments Centre (SHTAC) as an independent Evidence Review Group (ERG) to provide a critique of the manufacturer’s submitted evidence. Reslizumab is compared with best standard of care and omalizumab, for a small ‘overlap’ population of patients who have both eosinophilic and IgE-mediated severe asthma. This paper provides a summary of the ERG’s review of the manufacturer’s submission, and summarises the NICE Appraisal Committee’s subsequent guidance (issued in August 2017). The ERG considered that there were limitations in the approach proposed by the manufacturer for the exacerbation rate and the utility for severe exacerbation. The company amended their initial analysis, following comments from the ERG and the NICE committee, whereby the incremental cost effectiveness ratio was £29,870 per QALY gained for reslizumab compared with best standard care. The NICE Appraisal Committee (AC) concluded that reslizumab was recommended as an option for the treatment of severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids plus another drug, only if (1) the blood eosinophil count has been recorded as 400 cells per microlitre or more and (2) the patient has had three or more asthma exacerbations in the past 12 months, and (3) the company provides reslizumab with the discount agreed in the patient access scheme.
545-553
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Frampton, Geoff
26c6163c-3428-45b8-b8b9-92091ff6c69f
Harris, Petra
a8bd143b-3e2c-4929-9279-510a4c60bd09
Rose, Micah
f6deee44-f21f-4d14-90a9-f7a449d0adba
Chorozoglou, Maria
1d8dc56f-914a-402a-8155-4fb1e4380835
Pickett, Karen
1bac9d88-da29-4a3e-9fd2-e469f129f963
March 2018
Cooper, Keith
ea064f58-d71d-404a-bcf3-49d243b8825b
Frampton, Geoff
26c6163c-3428-45b8-b8b9-92091ff6c69f
Harris, Petra
a8bd143b-3e2c-4929-9279-510a4c60bd09
Rose, Micah
f6deee44-f21f-4d14-90a9-f7a449d0adba
Chorozoglou, Maria
1d8dc56f-914a-402a-8155-4fb1e4380835
Pickett, Karen
1bac9d88-da29-4a3e-9fd2-e469f129f963
Cooper, Keith, Frampton, Geoff, Harris, Petra, Rose, Micah, Chorozoglou, Maria and Pickett, Karen
(2018)
Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: An evidence review group perspective of a NICE single technology appraisal.
PharmacoEconomics, 36 (5), .
(doi:10.1007/s40273-017-0608-z).
Abstract
As part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) process, the manufacturer of reslizumab (Teva) submitted evidence for its clinical and cost effectiveness for the treatment of eosinophilic asthma inadequately controlled by inhaled corticosteroids. NICE commissioned Southampton Health Technology Assessments Centre (SHTAC) as an independent Evidence Review Group (ERG) to provide a critique of the manufacturer’s submitted evidence. Reslizumab is compared with best standard of care and omalizumab, for a small ‘overlap’ population of patients who have both eosinophilic and IgE-mediated severe asthma. This paper provides a summary of the ERG’s review of the manufacturer’s submission, and summarises the NICE Appraisal Committee’s subsequent guidance (issued in August 2017). The ERG considered that there were limitations in the approach proposed by the manufacturer for the exacerbation rate and the utility for severe exacerbation. The company amended their initial analysis, following comments from the ERG and the NICE committee, whereby the incremental cost effectiveness ratio was £29,870 per QALY gained for reslizumab compared with best standard care. The NICE Appraisal Committee (AC) concluded that reslizumab was recommended as an option for the treatment of severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids plus another drug, only if (1) the blood eosinophil count has been recorded as 400 cells per microlitre or more and (2) the patient has had three or more asthma exacerbations in the past 12 months, and (3) the company provides reslizumab with the discount agreed in the patient access scheme.
Text
Reslizumab for treating asthma v2
- Accepted Manuscript
More information
Submitted date: 20 October 2017
Accepted/In Press date: 11 December 2017
e-pub ahead of print date: 26 March 2018
Published date: March 2018
Identifiers
Local EPrints ID: 420055
URI: http://eprints.soton.ac.uk/id/eprint/420055
ISSN: 1170-7690
PURE UUID: 7a1bf727-094e-4c1c-ab18-392a310c101f
Catalogue record
Date deposited: 25 Apr 2018 16:31
Last modified: 16 Mar 2024 06:28
Export record
Altmetrics
Contributors
Author:
Petra Harris
Author:
Micah Rose
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics